| P50 | author | Tsepo Tsekoa | Q56858693 |
| | Craig J van Dolleweerd | Q57056505 |
| | Julian Ma | Q61124614 |
| | Yi-Hui Audrey Teh | Q62554966 |
| | Anthony R. Fooks | Q29557997 |
| | Ashley C. Banyard | Q37378859 |
| P2093 | author name string | Claude T Sabeta | |
| | Leonard Both | |
| | Clemens Gruber | |
| | Wonderful Shumba | |
| | Rachel K Chikwamba | |
| | Baby Phahladira | |
| | Ereck Chakauya | |
| | Hester C T Lotter-Stark | |
| P2860 | cites work | Passive immunity in the prevention of rabies. | Q38006132 |
| | Monoclonal antibodies for prophylactic and therapeutic use against viral infections. | Q38078178 |
| | The fight against rabies in Africa: From recognition to action | Q38974964 |
| | Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults | Q39547355 |
| | Equine rabies immunoglobulin: a study on its clinical safety. | Q39730585 |
| | Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates | Q40180565 |
| | Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin | Q40316237 |
| | Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses | Q40505899 |
| | Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies | Q40579109 |
| | Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis | Q40700170 |
| | A Rabies-Specific Human Monoclonal Antibody That Protects Mice Against Lethal Rabies | Q41662869 |
| | Growth of rabies virus in non-nervous tissue culture. | Q45719160 |
| | The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. | Q45744398 |
| | Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody | Q45754757 |
| | Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. | Q51901413 |
| | N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants | Q74629394 |
| | Differential N-glycosylation of a monoclonal antibody expressed in tobacco leaves with and without endoplasmic reticulum retention signal apparently induces similar in vivo stability in mice | Q84701678 |
| | Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants | Q24531953 |
| | Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides | Q28288481 |
| | Function and glycosylation of plant-derived antiviral monoclonal antibody | Q30728002 |
| | First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity | Q33370751 |
| | Rabies exposures, post-exposure prophylaxis and deaths in a region of endemic canine rabies | Q33386840 |
| | Novel vaccines to human rabies | Q33507253 |
| | Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans | Q33514828 |
| | Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity | Q33838289 |
| | Antibody degradation in tobacco plants: a predominantly apoplastic process | Q34114675 |
| | Quantifying antigenic relationships among the lyssaviruses | Q34296085 |
| | Rabies re-examined | Q34764816 |
| | Intracellular reprogramming of expression, glycosylation, and function of a plant-derived antiviral therapeutic monoclonal antibody | Q34962237 |
| | Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges | Q35172504 |
| | Emerging antibody products and Nicotiana manufacturing | Q35194874 |
| | Molecular Pharming: future targets and aspirations. | Q35592164 |
| | Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies | Q35814688 |
| | Clinical practice. Prophylaxis against rabies | Q35985865 |
| | A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis | Q36555948 |
| | Rabies remains a 'neglected disease'. | Q36593413 |
| | Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study | Q36787005 |
| | Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. | Q36788708 |
| | Biological characterization of human monoclonal antibodies to rabies virus | Q36808624 |
| | Rabies and African bat lyssavirus encephalitis and its prevention | Q37783763 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rabies | Q39222 |
| | rabies virus | Q698976 |
| | monoclonal antibody | Q422248 |
| | transgenic plant | Q123738414 |
| P304 | page(s) | 200-208 | |
| P577 | publication date | 2014-02-07 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody | |
| P478 | volume | 210 | |